In This Section

Program

Beginning at 3:00 p.m. on Friday, April 8, and continuing all day Saturday, April 9, 2022, the AACR Annual Meeting Program will include Educational Sessions and Methods Workshops. The program on Saturday will conclude with the Precancer Discovery Science Plenary Session. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 10. The meeting will conclude at 1:30 p.m. on Wednesday, April 13.

Plenary Sessions

Saturday, April 9, 2022
Precancer Discovery Science
Chair: Catriona H.M. Jamieson, UCSD Moores Cancer Center, La Jolla, CA

  • Avrum E. Spira, Johnson & Johnson and Boston University Medical Center, Boston, MA
  • Rebecca Fitzgerald, Hutchison/MRC Research Center, Cambridge, United Kingdom
  • Veronica Kinzler, The Francis Crick Institute, London, United Kingdom
  • Susan M. Domchek, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Sunday, April 10, 2022
Opening Plenary Session: Decoding Cancer Complexity, Integrating Science, Transforming
Patient Outcomes
Chair: Marcia R. Cruz-Correa, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR

  • Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
  • James M. Crawford, Yale University, West Haven, CT
  • Marcia C. Haigis, Harvard Medical School, Boston, MA
  • Nickolas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
  • Franziska Michor, Dana-Farber Cancer Institute, Boston, MA
  • Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY

Monday, April 11, 2022
Decoding Cancer Health Disparities: Integration of Complex Data and Diversity to Achieve Equity
Chair: Mariana C. Stern, USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Yu Shyr, Vanderbilt University Medical Center, Nashville, TN
  • Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA
  • Olusegun I. Alatise, Obafemi Awolowo University, Ile-Ife, Nigeria
  • Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Cheryl L. Willman, Mayo Clinic Comprehensive Cancer Center, Rochester, MN; and University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Tuesday, April 12, 2022
Precision Medicine for Immuno-oncology and the Promise for the Future
Chair: Carl H. June, University of Pennsylvania, Philadelphia, PA

  • Ton N. Schumacher, Netherlands Cancer Institute, Haarlem, The Netherlands
  • Thomas F. Gajewski, University of Chicago, Chicago, IL
  • Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY
  • Shannon J. Turley, Genentech, Inc., South San Francisco, CA

Wednesday, April 13, 2022
Tumor Evolution and Therapeutic Resistance
Chair: Anna D. Barker, Ellison Institute for Transformative Medicine, Los Angeles, CA

  • Emmanuelle Passegué, Columbia University Irving Medical Center, New York, NY
  • Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
  • Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY
  • Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Charles Swanton, The Francis Crick Institute, London, United Kingdom

Major Symposia

  • Adipose Tissue as a Driver of Carcinogenesis
  • Aging and the Tumor Microenvironment’s Impact on Minimal Residual Disease and Cancer Recurrence
  • Artificial Intelligence in Cancer Research and Care
  • Bone Metastasis
  • Cancer Evolution Biomarkers
  • Cancer Stem Cell Metabolism, Proteostasis, and Metastasis
  • Cancer Vaccines: New Developments and Clinical Response
  • Challenging Drug Targets
  • Clinical Progress with CD3 Bispecifics
  • Digital and Computational Histopathology: Taking Cancer Diagnostics to the Cutting Edge
  • Epigenetic Alterations as Cancer Therapeutic Targets
  • Epigenome Biology and Cancer
  • Extracellular Matrix Remodeling in Cancer
  • Extrachromosomal DNA: Origins and Significance
  • Genome Instability as a Driver of Cancer Evolution
  • Germline Mutations as Drug Targets
  • Identification of Cancer Dependencies
  • Immunoprevention and Clinical Trials
  • Immunotherapy for Solid Tumors and Blood Cancers in Adult and Pediatric Patients
  • Liquid Biopsy: From Discovery to Clinical Application
  • Macroenvironmental and Microenvironmental Drivers of Cancer Stem Cell Generation
  • Mechanisms of Cancer Stem Cell Immune Evasion
  • Mechanisms of Protein Degradation Chemistries for Cancer Therapy
  • Mechanisms of Structural Mutations in Cancer
  • Metabolism of the Tumor Microenvironment
  • Metastatic Organotropism
  • Microdosing and Drug Delivery
  • Modern Synthetic Lethality Strategies in Targeting the DNA Damage Response and Beyond: Moving beyond PARP and BRCA
  • Multiomics Approaches for Novel Oncopathogen Discovery and Related Mechanisms
  • Myeloid Targets to Enhance Therapeutic Antitumor Immunity
  • Nerves, Cancer, and Immunity
  • Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer
  • Novel Mechanisms for Targeting KRAS
  • Pathophysiology and New Treatments for Cancer-Associated Thrombosis
  • Physical Aspects of Cancer and Physical Sciences of Oncology
  • Predictive Biomarkers for Precision Radiation Oncology
  • Profiling Molecular Proximity in Cancer Research
  • Radiation and Immunotherapy
  • The Science of Survivorship
  • Screening, Detecting, Intervening Earlier in Clinical Care of Underserved Populations
  • Targeting Noncancer Syndromes with Cancer Drugs
  • The Crossroads between Epigenetic Regulation and Metabolism in Cancer
  • Tumor Dormancy
  • Understanding Microbe–Tumor Interactions in Health and Disease: From Basic Mechanisms to Applied Microbial-Based Cancer Therapy

Advances in Diagnostics and Therapeutics

  • Adjuvant versus Neoadjuvant Immunotherapy
  • Adoptive Cellular Therapy: Treatment for the Masses
  • Cancer Metabolic Phenotypes: A Precision Medicine Perspective for Radiation Oncology?
  • Clinical to Genetic Monitoring for Hereditary Cancers
  • Deep Learning for Cancer Imaging
  • Functional Precision Medicine
  • How Should Clonal Hematopoiesis Impact Cancer Treatment Decisions?
  • Interpreting and Building Trust in Artificial Intelligence Models
  • Machine Learning to Translate the Cancer Genome and Epigenome
  • New Developments in Immunotherapy: Targeting Cytokines
  • Next-Generation Costimulatory Receptor Agonists in Combination with CD3 Bispecific Antibodies
  • Peptide–Peptide Interaction Inhibitors in Cancer Therapeutics
  • Targeting Transcription Factors
  • Technologies to Understand Malignant Clonal Behavior at Single Cell Resolution
  • Theranostics for Patient Care

Advances in Organ Site Research

  • Advances in Bladder Cancer
  • Advances in Glioblastoma Cancer Research and Cancer Care
  • Advances in Neuroblastoma Research
  • Advances in Ovarian Cancer Screening and Treatment
  • Bone Marrow Immune Microenvironment
  • Breast Cancer Genomics in Latin America
  • Gastric Cancer: From Biology to Therapy
  • Models for Rare Cancers
  • New Targets for Prostate Cancer
  • Pediatric Tumors
  • Progress in Understanding Nonalcoholic Fatty Liver Disease-Induced Liver Cancer and Associated Disparities
  • Triple Negative Breast Cancer: Molecular Insights and Treatment Advances
  • Understanding Microbe–Tumor Relationships in Colorectal Cancer

Advances in Population Sciences

  • Functional Role of Long Tail Coding and Noncoding Mutations in Cancer
  • Impact of Off-Label Therapies in Cancer Care and Outcomes across Populations
  • Where You Live Matters: From Biological to Social Determinants of Cancer Outcomes

Advances in Prevention Research

  • Multicancer Screening Tests
  • The Role of Infection in Cancer
  • Tobacco and Smokeless Tobacco

Advances in the Science of Cancer Health Disparities

  • Implementation Science for Bridging Health Disparities
  • Molecular Epidemiology of Stress and Discrimination and Cancer Outcomes
  • Obesity and Health Disparities in Cancer

Forums

  • Addressing Health Disparities and Patient Distrust
  • Advances in Lung Cancer
  • Breaking Down Silos: If We Did It during the COVID Pandemic, Why Not for Cancer?
  • Choosing What Immuno-oncology Combinations to Use for Your Patient
  • How Can We Address the Disparate Risk of Cervical Cancer in Vulnerable Populations?
  • How Have GWAS/EWAS Studies Impacted Cancer Research?
  • Impact of Telehealth on Cancer Care Delivery
  • Oligometastatic Disease
  • Pancreas Cancer: Why Are We Moving So Slowly?
  • Precision Oncology for Pediatric Cancer
  • Untangling the Mechanisms of Resistance to Immune Checkpoint Blockade
  • Vaccine Effectiveness in Cancer Patients with Immunotherapy
  • What Is the Causal Link between Race and Early Onset of Colon Cancer?